The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval.” “We have seen the ...

Despite all efforts, cataract formation is inevitable with age. However, it can be delayed with the inclusion of certain vitamins that are taken regularly, which slows the formation and progression of ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing for wet AMD.

D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its ...